ZYME Zymeworks Inc revenue, earnings and financials
For the quarter ended June 30, 2026, Zymeworks Inc reported revenue of $4.59M (down 90.6% from a year earlier), net income of −$45.0M and diluted EPS of −$0.62; over the last four quarters revenue was $37.1M and net income −$150M; for the fiscal year ended December 2025 revenue was $106M, up 38.9% on the year before.
ZYME annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $106M, gross profit n/a, operating income −$92.5M, net income −$81.1M (margin -76.6%), EPS −$1.08
- Fiscal year ended Dec 2024: revenue $76.3M, gross profit n/a, operating income −$137M, net income −$123M (margin -160.8%), EPS −$1.62
- Fiscal year ended Dec 2023: revenue $76.0M, gross profit n/a, operating income −$138M, net income −$119M (margin -156.1%), EPS −$1.72
- Fiscal year ended Dec 2022: revenue $412M, gross profit n/a, operating income $131M, net income $124M (margin 30.1%), EPS $1.90
- Fiscal year ended Dec 2021: revenue $26.7M, gross profit n/a, operating income −$216M, net income −$212M (margin -794.0%), EPS −$4.61
ZYME quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $4.59M (down 90.6% year over year), net income −$45.0M, EPS −$0.62
- Quarter ended Mar 31, 2026: revenue $2.41M (down 91.1% year over year), net income −$44.2M, EPS −$0.59
- Quarter ended Dec 31, 2025 (from the annual report): revenue $2.52M (down 91.9% year over year), net income −$41.2M, EPS −$0.55
- Quarter ended Sep 30, 2025: revenue $27.6M (up 72.6% year over year), net income −$19.6M, EPS −$0.26
- Quarter ended Jun 30, 2025: revenue $48.7M (up 153.2% year over year), net income $2.32M, EPS $0.03
- Quarter ended Mar 31, 2025: revenue $27.1M (up 170.3% year over year), net income −$22.6M, EPS −$0.30
- Quarter ended Dec 31, 2024 (from the annual report): revenue $31.0M (up 83.3% year over year), net income −$23.5M, EPS −$0.32
- Quarter ended Sep 30, 2024: revenue $16.0M (down 3.1% year over year), net income −$29.9M, EPS −$0.39
- Quarter ended Jun 30, 2024: revenue $19.2M (up 174.8% year over year), net income −$37.7M, EPS −$0.49
- Quarter ended Mar 31, 2024: revenue $10.0M (down 71.8% year over year), net income −$31.7M, EPS −$0.42
- Quarter ended Dec 31, 2023 (from the annual report): revenue $16.9M (down 95.8% year over year), net income −$14.5M, EPS −$0.18
- Quarter ended Sep 30, 2023: revenue $16.5M (up 527.4% year over year), net income −$28.7M, EPS −$0.41
- Quarter ended Jun 30, 2023: revenue $7.00M (up 28.7% year over year), net income −$51.2M, EPS −$0.76
- Quarter ended Mar 31, 2023: revenue $35.6M (up 1756.9% year over year), net income −$24.4M, EPS −$0.37
- Quarter ended Dec 31, 2022 (from the annual report): revenue $402M, net income $309M, EPS $4.78
- Quarter ended Sep 30, 2022: revenue $2.63M (down 40.1% year over year), net income −$47.8M, EPS −$0.72
- Quarter ended Jun 30, 2022: revenue $5.44M, net income −$64.6M, EPS −$0.97
- Quarter ended Mar 31, 2022: revenue $1.92M, net income −$72.6M, EPS −$1.19
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$39.2M, EPS n/a
- Quarter ended Sep 30, 2021: revenue $4.40M, net income −$60.6M, EPS −$1.25
ZYME cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$33.0M, share buybacks $41.7M
- Fiscal year ended Dec 2024: operating cash flow −$110M, share buybacks $30.1M
- Fiscal year ended Dec 2023: operating cash flow −$118M, share buybacks $0
- Fiscal year ended Dec 2022: operating cash flow $144M, share buybacks $0
- Fiscal year ended Dec 2021: operating cash flow −$192M, share buybacks n/a
ZYME balance sheet
- Jun 30, 2026: cash $179M, total assets $397M, total liabilities $317M, shareholders' equity $80.4M
- Mar 31, 2026: cash $244M, total assets $478M, total liabilities $315M, shareholders' equity $164M
- Dec 31, 2025: cash $41.2M, total assets $347M, total liabilities $78.0M, shareholders' equity $269M
- Sep 30, 2025: cash $64.8M, total assets $397M, total liabilities $77.2M, shareholders' equity $320M
- Jun 30, 2025: cash $98.3M, total assets $408M, total liabilities $73.9M, shareholders' equity $335M
- Mar 31, 2025: cash $76.2M, total assets $426M, total liabilities $101M, shareholders' equity $325M
- Dec 31, 2024: cash $66.1M, total assets $463M, total liabilities $124M, shareholders' equity $339M
- Sep 30, 2024: cash $122M, total assets $487M, total liabilities $120M, shareholders' equity $367M
What is ZYME's revenue?
Zymeworks Inc reported $37.1M of revenue over its last four quarters, through June 30, 2026.
Is ZYME profitable?
No. Zymeworks Inc lost $150M over the last four quarters.
What is ZYME's EPS?
Diluted earnings per share over the last four quarters were −$2.02; −$0.62 in the latest quarter.